Diabetes · primary immunosuppression in kidney transplant recipients
Low probably leads to lower diabetes compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review
Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in lymphoma/PTLD compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review
Acne/rash · primary immunosuppression in kidney transplant recipients
Low showed no clear difference in acne/rash compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).
1 finding from 1 review
GRF (mL/min) · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Hypercholesterolaemia · primary immunosuppression in kidney transplant recipients
Low probably leads to lower hypercholesterolaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (moderate certainty).
1 finding from 1 review
Anaemia · primary immunosuppression in kidney transplant recipients
Low may leads to lower anaemia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Low may leads to lower thrombocytopenia compared with higher dose target of rapamycin inhibitor (TOR‐ I): secondary outcomes (low certainty).
1 finding from 1 review
Outcomes* · people with primary open‐angle glaucoma and no previous glaucoma surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Control of intraocular pressure · people with primary open‐angle glaucoma and no previous glaucoma surgery
Low‐ showed no clear difference in control of intraocular pressure compared with high‐energy diode trans‐scleral cyclophotocoagulation (low certainty).
1 finding from 1 review
Mean change in intraocular pressure · people with primary open‐angle glaucoma and no previous glaucoma surgery
1 finding from 1 review
Decrease in visual acuity · people with primary open‐angle glaucoma and no previous glaucoma surgery
Low‐ showed no clear difference in decrease in visual acuity compared with high‐energy diode trans‐scleral cyclophotocoagulation (low certainty).
1 finding from 1 review
Mean visual field · people with primary open‐angle glaucoma and no previous glaucoma surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean number of antiglaucoma medications at 1‐year · people with primary open‐angle glaucoma and no previous glaucoma surgery
1 finding from 1 review
Proportion needing additional glaucoma surgery at 1‐year · people with primary open‐angle glaucoma and no previous glaucoma surgery
Low‐ showed no clear difference in additional glaucoma surgery compared with high‐energy diode trans‐scleral cyclophotocoagulation (low certainty).
1 finding from 1 review
Adverse events: atonic pupil · people with primary open‐angle glaucoma and no previous glaucoma surgery
Low‐ showed no clear difference in adverse events: atonic pupil compared with high‐energy diode trans‐scleral cyclophotocoagulation (low certainty).
1 finding from 1 review
Death or bronchopulmonary dysplasia at 36 weeks PMA · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or bronchopulmonary dysplasia at 36 weeks PMA compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or cerebral palsy at 1 to 3 years · preterm infants at risk for bronchopulmonary dysplasia
Lower showed no clear difference in death or cerebral palsy at 1 to 3 years compared with higher cumulative dose dexamethasone regimen (low certainty).
1 finding from 1 review
Death or abnormal neurodevelopmental outcome (various definitions) · preterm infants at risk for bronchopulmonary dysplasia
It is very uncertain whether lower changes death or abnormal neurodevelopmental outcome (various definitions)… compared with higher cumulative dose dexamethasone regimen (very low certainty).
1 finding from 1 review
Selection · adults and children
1 finding from 1 review
Consumption · adults and children
1 finding from 1 review